SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SZOSTAK M ANNE
(Last) (First) (Middle)
ONE IDEXX DRIVE
(Street)
WESTBROOK ME 04092
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
05/06/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 05/06/2024 M 257 A $0 257 D
Common Stock 05/08/2024 G 257 D $0 0 D
Common Stock 05/08/2024 G 257 A $0 6,561(1) I Trust of M. Anne Szostak(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right-to-buy) $476.87 05/06/2024 A 609 (3) 05/05/2034 Common Stock 609 $0 609 D
Restricted Stock Unit (4) 05/06/2024 A 262 (4) (4) Common Stock 262 $0 262 D
Restricted Stock Unit (5) 05/06/2024 M 257 (5) (5) Common Stock 257 $0 0 D
Explanation of Responses:
1. Includes 1,604 shares of IDEXX Laboratories, Inc. common stock contributed by the reporting person to the Trust of M. Anne Szostak (as defined in note (2) below).
2. The reporting person is the settlor of the Trust of M. Anne Szostak ('Trust') and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust.
3. Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.
4. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.
5. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.
Remarks:
/s/ Lily J. Lu, Attorney-in-Fact for M. Anne Szostak 05/08/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Grafico Azioni IDEXX Laboratories (NASDAQ:IDXX)
Storico
Da Ott 2024 a Nov 2024 Clicca qui per i Grafici di IDEXX Laboratories
Grafico Azioni IDEXX Laboratories (NASDAQ:IDXX)
Storico
Da Nov 2023 a Nov 2024 Clicca qui per i Grafici di IDEXX Laboratories